Human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells have an enormous potential; however, their potential clinical application is being arrested due to various limitations such as teratoma formation followed by tumorigenesis, emergent usage, and the quality control of cells, as well as safety issues regarding long-term culture are also delaying their clinical application. In addition, human ES cells have two crucial issues: immunogenicity and ethical issues associated with their clinical application. The efficient generation of human iPS cells requires gene transfer, yet the mechanism underlying pluripotent stem cell induction has not yet been fully elucidated. Otherwise, although human adult regenerative cells including mesenchymal stem cells have a limited capacity for differentiation, they are nevertheless promising candidates for tissue regeneration in a clinical setting. This review highlights the use of regenerative cells for transplantation in hepatic failure.
INTRODUCTION
cells have been investigated for hepatic differentiation ability, using mostly mouse, but also monkey and human, ES cells (49) . Mouse ES cells have been directly Severe hepatic failure, such as hepatic cirrhosis and hepatocarcinoma, is not reversible. The only effective differentiated into functional hepatocytes in an adherent monoculture condition using a hepatic induction factor treatment to date is orthotropic liver transplantation, but alternative approaches are needed because of the limited cocktail (HIFC) method (98, 108) . Growth factors directing hepatic fate specification have been identified on the number of donors and organ rejection. One such approach is regenerative medicine, which holds promise basis of an in vivo transplantation of ES cells into liverinjured animals (106) . Soto-Gutiérrez et al. demonfor the development of a cell-based therapy of the liver (113) and may allow the transplantation of hepatocytestrated that approximately 70% of differentiated mouse ES cells express albumin following coculture with like cells generated from stem cells (4, 8, 94) . The establishment of stem cell therapy requires multipotential, human liver nonparenchymal cell lines and that the albumin-positive cells can be recovered by albumin proimmunocompatible stem cells and a direct differentiation strategy that is not followed by posttransplantation moter-based cell sorting. The sorted cells produce albumin in culture and metabolize ammonia, lidocaine, complications or unwanted differentiation such as tumor formation. The cells are capable of supporting a host's and diazepam at approximately two thirds the rate of primary mouse hepatocytes (90) . Chen et al. developed liver function and thereby can open the way to further treatment options and liver regeneration.
an efficient method for differentiating the human ES cell line KhES-1 into hepatocyte-like cells in vitro using 50 ng/ml of activin A and 500 ng/ml of a deleted variant of PLURIPOTENT STEM CELLS hepatocyte growth factor (dHGF) (21) . Similarly, SotoGutiérrez et al. demonstrated the efficient differentiation Human embryonic stem (ES) cells can be harvested from human blastocysts in human embryos (100) . ES of hES cells to functional hepatocytes using HGF and dpoly-amino-urethane-coated nonwoven polytetrafluoremains controversial (39, 41, 68, 74, 82, 87, 116, 117) . Among the proposed ideas is the hypothesis of the paracrine roethylene fabric (89) . In addition, Basma et al. reported that human ES cells can be differentiated into cells with effects of MSCs, by which an amelioration of liver damage occurs through the secretion of active factors (69, 70) . many characteristics of primary human hepatocytes. Hepatocyte-like cells can be enriched and recovered Therefore, human adult regenerative cells including multipotent stem cells are promising candidates for liver based on asialoglycoprotein receptor expression and potentially could be used in drug discovery research and regeneration (39, 68, 72, 82, 85, 99) , and their usage might sidestep obstacles, such as ethical concerns and risks of developed as therapeutics (10) . However, human ES cells have two crucial issues: immunogenicity and ethical rejection. The most promising regenerative cells are MSCs, found in human bone marrow (BM) (74), adipose tissue issues in clinical usage.
Generating pluripotent stem cells from the postnatal (116, 117) , scalp tissue (87), placenta (41), and umbilical cord blood (UCB) (13) as well as in various fetal tissues tissue of an individual patient would greatly facilitate their therapeutic application by avoiding the ethical issues and (17) . These stem cells can differentiate in vitro into multiple types of lineages such as: chondrogenic, osteogethe immune rejection by the recipient, which are associated with allograft transplants (38, 109) . Recently, it was nic, adipogenic (74), myogenic (30) , neurogenic (81) , and hepatogenic (39, 68, 82, 85) , depending on the microshown that a specific set of genes can induce pluripotent stem cells from human fibroblasts (57, 61, 71, 92, 112) . environment in which they reside. MSCs from BM and UCB have been differentiated into a hepatic lineage; Human induced pluripotent stem (iPS) cells are similar to human embryonic stem cells in morphology, gene however, the question of whether these are the best sources of stem cells for hepatic replacement and/or expression, cell surface antigens, long-term self-renewal ability, and teratoma formation and that human leukoregeneration remains. cyte antigen (HLA) genotypes of human iPS cell lines BONE MARROW-DERIVED were identical to those of their respective parental REGENERATIVE CELLS somatic cells (61) . However, at present, gene transfer is essential for the efficient generation of human iPS cells, A well-characterized BM stromal cell population (74) emerged as a focus for regenerative therapy. There is a and the mechanism underlying pluripotent stem cell induction has not yet been fully elucidated. Although little confusion in terminology, with some authors suggesting (23) that subpopulations named colony forming human iPS cells have an enormous potential, many limitations such as teratoma formation followed by tumoriunits of fibroblasts (CFU-F), multipotent adult progenitor cells (MAPCs) (85) (115) . We adapted the HIFC system to contribcyte metabolic and secretion activities following hepatocyte isolation. They clearly demonstrate the usefulness of ute to hepatic differentiation of human BM-derived MSCs (96). Hepatocytes derived from human MSCs SAPNF for maintaining the differentiated functions of porcine hepatocytes in culture (65) . The demonstrated reveal morphological, biological, functional, and therapeutic potential.
results of 3D cultures along with advances in stem cell technology might serve in the future as a basis for the Therefore, MSCs represent a promising tool for cell transplantation. They can be obtained from the patient's development of an artificial liver. Soto-Gutiérrez et al.
reported that treatment of 90% hepatectomized mice own bone marrow, expanded in vitro, and then transplanted back into the liver as a native source for hepatic with a subcutaneously implanted bioartificial liver (BAL) seeded with ES cell-derived hepatocytes or priregeneration or, after differentiating ex vivo, maintained on a proper scaffold and transplanted back into a dismary hepatocytes improved the liver function and prolonged survival (88) . eased liver. In the future, stem cell-derived hepatocytes might be used together with advanced tissue engineering ADIPOSE TISSUE-DERIVED technology for the development of the entire liver system.
REGENERATIVE CELLS TISSUE ENGINEERING AND BIOMATERIALS
The number of laboratories studying adipose tissue has increased dramatically since Zuk et al. reported on The microenvironment for long-term culture with a possibility to maintain stem cell-derived hepatocyte the identification of an adherent, multipotent cell from adipose tissue (117). Adipose tissue has been shown to functions is important in the context of stem cell-based liver therapy and tissue engineering (37) . The ideal scafbe a source of MSCs for regenerative medicine (84, 116, 117 (53) are considered to be the multipotent utilized, mainly poly(lactide-co-glycolide) (54), polyurethane, collagen, chitosan, alginate, and hydrogel. In the fraction of adherent cells, which, after the isolation of the adipose stromal vascular fraction (SVF), attach three-dimensional (3D) culture system, using poly-Npara-vinylbenzyl-lactonamide (PVLA)-coated reticulated themselves to plastic culture dishes and then remain there as a heterogeneous population of fibroblast-like polyurethane, Sato et al. maintained specific hepatocyte functions for up to 40 days in an in vitro culture. When cells. AT-MSCs are very similar to BM-MSCs (24,104).
Besides the fact that they are more heterogeneous (104), transplanted into the peritoneal cavity of rats, the hepatocytes were able to survive and retain liver-specific they have also been reported to demonstrate a surface antigen marker profile (33, 43, 44, 104) and differentiation functions for more than 1 month (83). Ohashi et al. successfully engrafted and maintained hepatocytes at extrapotential similar to BM-MSCs (18, 26, 40, 80, 86, 91) . ATMSCs are characterized as CD45
− hepatic sites, with extracellular matrix components for over 100 days (67) . In a first-time demonstration, we (14) ; however, there is confusion regarding CD34 marker. One of the markers defining MSC provenance show that ES cell-derived hepatocytes were capable of being maintained for a long time in a 3D culture with a is CD105 (endoglin) (35, 56) . CD105 is a component of the receptor complex of transforming growth factor-β porous hyaluronate (3D-HA) sponge (97). There is clear evidence that 3D-HA sponge formed hepatocyte spher-(TGF-β), a pleiotropic cytokine involved in cellular proliferation, differentiation, and migration. CD105 + cells oids within the pores and sustained cell viability and liver functions, such as albumin secretion, ammonia from bone marrow display more colony-forming unitfibroblasts (CFU-Fs) and revealed a capacity to form detoxification, and urea nitrogen synthesis for a prolonged time (more than 20 days), in comparison to a bone in vivo (3) and differentiate into a chondrogenic lineage (59) . The adipogenic and myogenic differentiaconventional monolayer culture and in collagen sponge cultures (17 days). Hepatocytes within an HA sponge tion ratio of CD105 + BM-MSCs is not influenced by the age of the donor; however, the ratio usually decreased lipoaspirate yields approximately 40-fold more stem cells than from 40 ml of marrow. Even though adipose in older patients (6) . The ratio of the number of CD105 + stem cells in adipose tissue to the age of the donor is tissue provides a more heterogeneous population of stem cells, the potential number of AT-MSCs is still suffistill not clear, and little is known about the relationship between disease (e.g., cancer) and stem cell potential.
ciently large to allow the selection/sorting of the multipotential fraction of AT-MSCs. The CD105 + fraction from BM-MSCs has more homogeneity and a greater Therapeutic Potential of Differentiated Cells ability to form CFU-Fs (3, 59, 77) . Some scientists have used other isolation procedures to select multipotent ATThe possibility for future application of AT-MSCs in the therapy of liver diseases is very promising. A preMSCs (76); however, the study described above used a CD105 + fraction using magnetic beads. The CD105 + vious study evaluated the hepatogenic potential of AT-MSCs. AT-MSCs from nonobese cancer patients fraction of BM-MSCs is age resistant (77) , and therefore sorting might be very useful because many patients with undergoing a gastrectomy were used because therapy concerns patients, not healthy donors. Magnetically liver failure or hepatocarcinoma tend to be elderly. Large amounts of fat are discarded during liposuction, activated cell-sorting (MACS) of the CD105 fraction yielded a multipotent and homogeneous subpopulation and, in the future, this valuable resource could be used for the isolation of AT-MSCs, which might then be of cells. CD105
+ AT-MSCs were highly inducible into the hepatic lineage, and derived hepatocyte-like cells stored in each patient's cell bank or cell products. The hepatic differentiation of CD105 + AT-MSCs expressed the liver markers, proteins, enzymes, and functions of human primary hepatocytes. The differentiresults in the generation of functional and transplantable hepatocytes (60-85%). Unfractionated AT-MSCs reveal ation potential of AT-MSCs was demonstrated by in vivo transplantation into immunodeficient mice, which hepatogenic potential as well; however, the ratio of differentiation is relatively lower (20-60%). The hepatoresulted in the incorporation of AT-MSC-derived hepatocytes into the CCl 4 -injured liver.
genic potentiality of AT-MSCs is confirmed by the detection of hepatic-specific markers and biochemical Therefore, human AT-MSCs, which might be obtained from a large number of cells, represent a very functions. The major protein produced by the hepatocytes, albumin, is synthesized and secreted into a medium attractive tool for future stem cell therapy of liver diseases. Transplantation of hepatocytes might become at days 30 and 50 (subsequently: 5 and 14 mg/dl/4 days/ 10 6 cells). The expression and activity of the microsome easier, more efficient, and safer than whole organ transplantation to cure patients suffering from end-stage liver cytochrome P450 (CYP) enzymes involved in drug, xenobiotic metabolism, and sterol and bile acid synthedysfunction. The maintenance of hepatocyte function in vitro is difficult if not nearly impossible, thus the sis indicates hepatocyte specificity. Hepatocyte-like cells generated from CD105 + AT-MSCs express CYP7A1, generation of stem cell-derived hepatocytes holds considerable promise for future clinical applications. The CYP1A1, CYP2C9, CYP3A4, and nicotinamide adenine dinucleotide phosphate (NADPH)-CYP reductase. hepatogenic potential of MSCs from different sources has been previously described (39, 68, 82, 85) . There have Therefore, these findings suggest that there might be some value in in vitro preclinical drug investigations. been two reports so far indicating the endoderm differentiation capacity of AT-MSCs: insulin-, somatostatin-, Transplantation experiments of AT-MSC-generated hepatocytes into CCl 4 -injured nude mice revealed direct and glucagon-expressing cells (101) as well as albuminand α-fetoprotein-expressing hepatocyte-like cells with incorporation into the liver, which was confirmed by human albumin immunostaining. This induction system the ability to synthesize urea and uptake low-density lipoproteins (LDL) (86); however, the second reported does not require coculturing, and therefore the undesired cell-cell interactions can thus be reduced. Nevertheless, system includes the use of dimethyl sulfoxide (DMSO), which has been shown to maintain hepatic morphology.
further studies examining the in vivo mechanism of homing, engraftment, and liver regeneration need to be In contrast, a preferable system simulates in vivo endoderm development of the liver, as previously reported performed in order to eliminate posttransplantation complications. Some in vivo functions, such as the serum (35, 56) . The isolation ratio and minimal decline in donor health associated with isolation of these cells suggests ammonia level and alanine aminotransferase (ALT), decreased after the transplantation of undifferentiated that AT-MSCs represent an attractive tool for studies on stem cell therapy for the liver. MSCs from a predomi-AT-MSCs as well. These findings indicate the possibility of the in vivo differentiation of AT-MSCs caused by nant source, such as bone marrow, reveal a lower proliferation capacity and frequency than AT-MSCs (76), and a regeneration microenvironment. The subsequent interaction of transplanted undifferentiated MSCs with liver their frequency is influenced by age, gender, the presence of osteoporosis, and prior exposure to high-dose parenchyma cells also needs to be evaluated in the context of the promotion of fibrosis (78), cancer, or liver chemotherapy or radiation. Importantly, 200 ml of dysfunction. Another topic of interest deserving evaluatime interval of transcription initiation (107), and thus regulate the transactivation of several endoderm and tion is the correlation between such factors as donor age, cancer history, and the differentiation potentiality of hepatocyte-specific factors, including transthyretin, albumin, and tyrosine aminotransferase (22, 28) . HNF3b/forstem cells. It should be emphasized that three independent donor-derived CD105 + AT-MSCs show similar khead box A2 (FOXA2) plays an important role in endoderm specification and subsequent hepatocyte difhepatic differentiation ability. In the context of clinical application, the use of AT-MSCs, which can be ferentiation both in vivo and in vitro (15, 52) . In this study, the induction of HNF3b/FOXA2 expression was obtained from a patient's own tissue in contrast to highly potent ES cells, would eliminate many obstacles clearly seen in AT-MSC-Hepa by a microarray analysis. Furthermore, the expression of other hepatic transcripsuch as ethical issues, rejection, and the risk of teratoma and tumor formation. tion factors, including HNF3a/FOXA1, GATA4, HNF6/ onecut homeobox 1 (ONECUT1), and HNF1 were The Transcriptome and Signal Pathways observed to be 10-fold upregulated in AT-MSC-Hepa in in Hepatic Differentiation comparison to undifferentiated AT-MSCs. These results suggest that the transcription factor networks are precisely The cells generated from AT-MSCs are transplantable hepatocyte-like cells with functional and morphoregulated in the hepatic differentiation system, and that the AT-MSCs differentiate into mature hepatocytes. logical similarities to hepatocytes. AT-MSC-derived hepatocytes (AT-MSC-Hepa) demonstrate several liverRapid Hepatic Fate Specification specific markers and functions, such as albumin production, LDL uptake, and ammonia detoxification. This
Clinical applications in the future would require a special approach, such as shortening the ex vivo manipsystem induces transplantable cells with morphological and functional characteristics of hepatocytes (7) . Other ulations as much as possible, including cultivation and direct hepatic fate. Therefore, an attempt was made to groups have also provided evidence of hepatic differentiation from human AT-MSCs (86, 93) . However, the modify the hepatocyte differentiation strategy, based on the current knowledge on in vivo mouse fetal liver molecular mechanisms underlying the differentiation of AT-MSCs are still largely unknown. None of the reports development (5). A period as short as 13 days is required and this strategy is enriched by pretreatment provide a comprehensive analysis of the process underlying the differentiation of AT-MSCs into hepatocytes.
with activin A and FGF-4. In addition, the content of the growth factor cocktail was reorganized and enriched Therefore, the molecular events involved in controlling the plasticity of AT-MSCs that give rise to hepatocytes with the addition of DMSO, nicotinamide, and insulintransferrin-selenium. This protocol yielded functional were investigated (7) . A microarray analysis showed that the gene expression pattern of AT-MSC-Hepa is hepatocyte-like cells in a much shorter period of time. Consequently, hepatocyte-like cells differentiated from similar to that of adult human hepatocytes and liver. Moreover, the enriched categories of genes and the sigadipose-derived stem cells (ASCs) were transplanted into immunodeficient mice with nonsevere acute liver naling pathways in the AT-MSC-Hepa were relevant to liver-specific functions. An analysis of the gene ontolinjury. These results showed a significant decrease of ammonia, aspartate aminotransferase (AST), ALT, and ogy (GO) groups indicated that many of the 1639 up-or downregulated genes belonged to GO categories releuric acid (UA) in the blood plasma of mice after the transplantation of hepatocyte-like cells from ASCs. vant to hepatic function, including the steroid and lipid metabolisms. In addition, a gene signaling pathway analThese results therefore show very important progress towards the further establishment of an alternative and ysis has identified gene signals that are remarkably activated in AT-MSC-Hepa, and these signals are also successful therapy for liver disease. The functional benefits of transplantation of the hepatocyte-like cells from upregulated in the whole liver. Therefore, a microarray analysis provides a potentially valuable resource for ASCs may be because of the functional support of the transplanted cells. The mechanisms by which the transdetermining the key molecules involved in hepatocyte differentiation and function. These integrative perspecplanted cells improve the functioning of the liver remain unclear. The support and activation of endogenous protives on the gene expression profile might be useful for revealing the control of plasticity of AT-MSCs that give genitors are possible factors. Further studies examining the in vivo mechanism of homing, engraftment, liver rise to hepatocytes. The expression of liver-selective transcription factors, such as hepatocyte nuclear factors regeneration, and the trophic effects need to be conducted. Hepatic disease is accompanied by inflammation and fibrosis in a heterogeneous condition, and so far no deficient mice 24 h after transplantation. Few positive cells were observed in different areas of the liver such effective treatment strategy has yet been established. Kupffer cells and liver macrophages are major sources as parenchyma, vessel, and bile duct. Monitoring AT-MSC migration, mobilization, and engraftment for a of IL-1β and tumor necrosis factor-α (TNF-α) production. These cytokines enhance the expression of adhelonger time is essential and very informative. Evaluating the effect of AT-MSCs on endogenous progenitor actision molecules in endothelial cells, which mediate neutrophil adhesion to endothelial cells causing cell dysvation has proven to be interesting (60) . There may be a different response of oval cells in vivo between mice function and destruction, leading to hepatocyte necrosis (31) . MSCs secrete a broad spectrum of active cytoand rats as well as in the injury model (42) . The possible actions of AT-MSCs in vivo are that they act directly kines, chemokines, and growth factors. AT-MSCs produce significantly more bioactive factors than BM-MSCs, by causing intracellular signaling and/or indirectly by secreting or making other cells in the vicinity secrete and, therefore, they may have either an equal or even stronger regenerative effect than BM-MSCs. This issue functionally active agents. However, involvement may be in part due to the pleiotrophic contribution through is highly interesting and needs precise evaluation by using MSCs isolated from adipose tissue and bone marthe direct and/or indirect activity of AT-MSCs. Actually, according to several recent noteworthy reports, row from the same donor. AT-MSCs secrete many active factors in vitro, among them immunosuppressive generalized administration of the culture supernatant from MSCs alone is successful in effectively prolonging IL-1RA, hepatocyte growth promoting IL-6, IL-8, HGF, NGF, MCP-1, and hematopoiesis promoting G-CSF, the lives of model animals with life-threatening liver damage (70,103). The in vitro production of cytokines/ GM-CSF, and that they are secreted in a larger volume than both BM-MSCs and NHDFs. IL-1RA is a strong growth factors by AT-MSCs was evaluated and compared with undifferentiated BM-MSCs and normal anti-inflammatory cytokine that binds to IL-1 receptors and inhibits the binding of IL-1α and IL-1β. Therefore, human dermal fibroblasts (NHDFs). This revealed a higher secretion of interleukin (IL)-1 receptor antagonist the immune activity of IL-1α and 1β is neutralized. Inflammatory cytokines such as IL-1 and TNF-α are not (IL-1RA), IL-6, IL-8, granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimuproduced by AT-MSCs or by BM-MSCs or NHDFs. On the other hand, IL-6, identical to hepatocyte-stimulatory lating factor (GM-CSF), monocyte chemotactic protein-1 (MCP-1), nerve growth factor (NGF), and HGF by factor (HSF), elicits an acute phase response in liver cells; IL-8 and MCP-1 are inflammatory-related factors, AT-MSCs, as opposed to BM-MSCs and NHDFs. However, vascular endothelial growth factor (VEGF) was although it is difficult to predict their actual in vivo activity. In fact, IL-6 together with TNF-α is responsible secreted similarly by both types of MSCs higher than by NHDFs. This in vitro study shows a higher production for a hepatocyte entering to the state of replication competence (95). IL-6, IL-8, and MCP-1 are produced by of bioactive factors in AT-MSCs than in BM-MSCs. Moreover, this in vivo study shows the ability of AThuman intrahepatic biliary epithelial cells through the TLR (toll-like receptor), 4-NF (nuclear factor)-κB, and MSCs to incorporate into the liver and improve its function. The regenerative ability of AT-MSCs may be MAPK (mitogen activated protein kinase) signaling pathways, and that they are possibly mediating an innate possibly due to trophic activity of AT-MSCs.
Therefore, undifferentiated AT-MSCs have the abilimmune-system function and modulating hepatic regeneration in vivo (46, 110) . HGF and TGF-α stimulate proity to restore and improve liver functions and promote liver recovery in mice with liver injury. Parameters such liferation of hepatocytes in the proliferation phase. HGF, which is proapoptotic for liver stellate cells as well as as AST, ALT, ALP, UA, and ammonia decrease in injured mice after AT-MSC transplantation, suggesting for myofibroblasts (45), acts as an anticirrhotic agent. Stellate cells are a major source of collagens and other that AT-MSCs have the ability to regenerate the liver. extracellular matrix (ECM) proteins in liver fibrosis. In paracrine-mediated actions (64) . Akt-modified MSCs can upregulate the expression of several candidate mediaddition, they regulate matrix metalloproteinases (MMP). Other highly secreted factors by AT-MSCs ators such as VEGF, FGF2, HGF, and insulin-like growth factor-1 (IGF-1), secreted frizzled related protein were G-CSF, GM-CSF, and IL-6, considered as a supporting process of hematopoiesis. There is evidence that 2 (SFRP2), which is the key Akt-modified-MSC released paracrine factor. Of note, these data show only many tissues contain their own multipotential stem cells (11, 12) (2, 29, 32, 66, 75) , and their mRNA and protein levels become elevated in association with
The most promising perspectives for cell transplantation would be to use uncultured (freshly isolated) regenhepatocyte proliferation induced by, for example, administration of CCl 4 (66) . NGF, like HGF, induces the erative cells in clinical application. Adipose tissue is an abundant source of regenerative cells that is easily harapoptosis of stellate cells (2, 29, 66) . NGF is secreted by cholangiocytes and also induces their proliferation (32) .
vested. Such adipose tissue-derived regenerative cells (ADRCs) include adipose-derived mesenchymal stem or In addition, MSCs can inhibit the proliferative and fibrogenic function of activated stellate cells in a paracrine progenitor cells and mesenchymal cells such as vascular cells and hematopoietic cells (Fig. 1) . Similar to manner. This inhibition is caused by MSC-derived IL-10 and TNF-α, which act synergistically. The secretion BM-MSCs, AT-MSCs can differentiate into multiple functional phenotypes with potential regenerative appliof IL-10 by MSCs is a response to IL-6 secretion by activated stellate cells. These events are not detected cations. Cytori Therapeutics, Inc., has developed a closed system called Celution TM System to isolate and while stellate cells are cultured with fibroblasts. The production of trophic agents by AT-MSCs exhibit donor concentrate ADRCs including mesenchymal stem and progenitor cells automatically from adipose tissue (55) . to donor variations. In fact, the secretion of IL-10 was detected in AT-MSCs of one donor only. Recently, AktADRCs can be processed by Celution TM System within the time frame of a single surgical procedure and are modified MSCs are proposed to be candidate cells for equivalent to those isolated manually. A therapeutic cells/ml bone marrow, and at a stem cell frequency of ϳ1:100,000; thus, a bone marrow aspirate of 40 ml yields dose of ADRCs can be prepared aseptically with the Celution TM System in nonspecified areas such as medical 1.2 × 10 4 BM-MSCs. In comparison, ϳ2 × 10 6 nonbuoyant mononuclear cells can be harvested per milliliter of clinics and hospitals; thus. this system could provide a "real-time treatment setting at the bed side" that is costadipose tissue and at a frequency of ϳ1:100, and 1.6 × 10 7 ADRCs can be isolated (62, 63, 111) . Therefore, an effective and safe (Fig. 2) 
